Allurion Technologies, Inc.

ALUR Healthcare Medical Devices

Allurion Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $15.2 million, down 52.6% from fiscal 2024. In the quarter to March 2026, revenue fell 47.2%, EPS fell 46.5% and free cash flow grew 66.0%, each against the same quarter a year earlier.

0.48 0.12 −20.00%
Market cap
$16.7M
P/E
0.0×
Fwd P/E
−0.7×
Dividend yield
—
F-score
2/9
Altman Z
−29.57
Beneish M
−2.91
Dividend safety
n/a
Older periods Jun '25 Sep '25 Dec '25 Mar '26
Piotroski F-Score

+8 more TTM periods

3 1 2 2
ROE
17.40% 43.77% 37.06% 45.16%
ROA
(31.34%) (93.92%) (118.37%) (127.26%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(84.60%) (720.00%) 118.40% 134.87%
Average Days of Receivables
107.17 84.48 94.69 100.69
Free Cash Flow per Share
(85.89) (71.26) (57.51) (25.49)
Free Cash Flow
(41.82) (36.90) (28.95) (22.70)
Other line items

Show all line items

Columns are period end dates